Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Deeks

Showing results (101-110 of 662) with videos related to

Pageof 67
Sort By:
Antiviral Therapy|June 9, 2006
A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtideGeorge Beatty, Peter Hunt, Anna Smith, et al.
AIDS Research and Human Retroviruses|August 23, 2011
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summarySusan F Plaeger, Brenda S Collins, Runa Musib, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 7, 2021
Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent SymptomsMichael J Peluso, Isaac J Thomas, Sadie E Munter, et al.
Plos One|April 18, 2014
Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirsBasile Siewe, Jennillee Wallace, Sonya Rygielski, et al.
Nature Medicine|October 24, 2025
How HIV research drives health innovation in multiple diseasesLawrence Corey, Jirair Ratevosian, Chris Beyrer, et al.
AIDS (London, England)|April 26, 2011
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected personsAndy I Choi, Eric Vittinghoff, Steven G Deeks, et al.
The Journal of Infectious Diseases|September 27, 2003
Assessing resistance costs of antiretroviral therapies via measures of future drug optionsHongyu Jiang, Steven G Deeks, Daniel R Kuritzkes, et al.
Circulation|January 27, 2010
Association between kidney function and albuminuria with cardiovascular events in HIV-infected personsAndy I Choi, Yongmei Li, Steven G Deeks, et al.
AIDS (London, England)|March 28, 2003
Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapyMark A Jacobson, Lea Liu, Hassan Khayam-Bashi, et al.
Plos Pathogens|January 16, 2019
Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latencyZichong Li, Jun Wu, Leonard Chavez, et al.
Pageof 67

Showing results (101-110 of 662) with videos related to

Sort By:
Pageof 67
Antiviral Therapy|June 9, 2006
A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtideGeorge Beatty, Peter Hunt, Anna Smith, et al.
AIDS Research and Human Retroviruses|August 23, 2011
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summarySusan F Plaeger, Brenda S Collins, Runa Musib, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 7, 2021
Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent SymptomsMichael J Peluso, Isaac J Thomas, Sadie E Munter, et al.
Plos One|April 18, 2014
Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirsBasile Siewe, Jennillee Wallace, Sonya Rygielski, et al.
Nature Medicine|October 24, 2025
How HIV research drives health innovation in multiple diseasesLawrence Corey, Jirair Ratevosian, Chris Beyrer, et al.
AIDS (London, England)|April 26, 2011
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected personsAndy I Choi, Eric Vittinghoff, Steven G Deeks, et al.
The Journal of Infectious Diseases|September 27, 2003
Assessing resistance costs of antiretroviral therapies via measures of future drug optionsHongyu Jiang, Steven G Deeks, Daniel R Kuritzkes, et al.
Circulation|January 27, 2010
Association between kidney function and albuminuria with cardiovascular events in HIV-infected personsAndy I Choi, Yongmei Li, Steven G Deeks, et al.
AIDS (London, England)|March 28, 2003
Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapyMark A Jacobson, Lea Liu, Hassan Khayam-Bashi, et al.
Plos Pathogens|January 16, 2019
Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latencyZichong Li, Jun Wu, Leonard Chavez, et al.
Pageof 67